References
- American Lung Association Epidemiology and Statistics Unit. Trends in Asthma Morbidity and Mortality, January 2001
- Centers for Disease Control and Prevention. CDC Surveillance Summaries: Surveillance for Asthma, United States, 1960–1995. MMWR Morb Mortal Wkly Rep 1998; 47(SS-1): 6–15
- Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2- agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325(6):388–92
- Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and of an inhaled beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90(1):32–42
- Waalkens HJ, Gerritsen J, Koeter GH, et al. Budesonide and terbutaline or terbutaline alone in children with mild asthma: effects on bronchial hyperresponsiveness and diurnal variation in peak flow. Thorax 1991; 46(7):499–503
- National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. NIH Publication No. 97–4051. Bethesda, MD: National Institutes of Health, 1997
- O'Byrne PM, Cuddy L, Taylor DW, et al. The clinical efficacy and cost benefit of inhaled corticosteroids as therapy in patients with mild asthma in primary care practice. Can Respir J 1996; 3(3): 169–75
- Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulm Pharmacol 1996; 9(1):19–27
- Thorsson L, Edsbacker S, Conradson TB. Lung deposition from budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7(10): 1839–1844
- Newman SP, Millar AB, Lennard-Jones TR, et al. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax 1984; 39(12):935–941
- Thompson J, Irvine T, Grathwohl K, et al. Misuse of metered-dose inhalers in hospitalized patients. Chest 1994; 105(3):715–7
- Kamada AK, Szefler SJ, Martin RJ, et al. Issues in the use of in haled steroids. Am J Respir Crit Care Med 1996; 153(6Pt 1):1739–48
- Barnes P. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J Allergy Clin Immunol 1998(4 Pt 2); 101:S427–33
- Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157(3 Pt2):S1–53
- Woodcock A. Effects of inhaled corticosteroids on bone density and metabolism. J Allergy Clin Immunol 1998; 101(4 Pt 2):S456–9
- Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343(15):1064–9
- The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343(15): 1054–63
- Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337(1):8–14
- Mitchell P, Cumming RG, Mackey DA. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology 1999; 106(12):2301–6
- Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339(17): 1194–200
- Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88(5):373–81
- Haahtela T, Järvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331(11):700–5
- Selroos O, Pietinalho A, Löfroos A-B, et al. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108(5):1228–34
- Overbeek S et al. Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch Chronic Nonspecific Lung Disease Study Groups. Chest 1996; 110(1):35–41